Clorox Co Del SEC Filings

Inovio Pharmaceuticals, Inc. (Nasdaq: INO) has filed a preliminary prospectus supplement under its effective shelf to raise capital through a combined offering of: (i) shares of common stock or pre-funded warrants (exercise price $0.001) in lieu of common stock, (ii) Series A warrants, and (iii) Series B warrants. Every share (or pre-funded warrant) will be sold together with one Series A warrant and one Series B warrant, although the securities are immediately separable upon issuance.

• Pricing & size: Key economics—number of securities, combined public price, underwriting discount, and gross/net proceeds—remain blank pending final marketing, but the filing authorizes a 30-day overallotment option for additional shares and warrants.
• Warrant profile: • Series A warrants are exercisable immediately, expire on the earlier of (a) 30 days after FDA accepts a Biologics License Application (BLA) for INO-3107 or (b) 12 months after issuance; • Series B warrants are exercisable immediately and expire five years after issuance. Neither series will be listed, limiting liquidity.
• Use of proceeds: Management plans to direct funds to (1) advancement of its DNA-medicine clinical pipeline—including a rolling BLA submission for lead asset INO-3107 in recurrent respiratory papillomatosis expected to begin mid-2025, (2) potential commercial launch preparation for INO-3107 if approved, and (3) general corporate purposes.
• Dilution & risk: The company warns that investors will incur immediate dilution; further dilution could arise from outstanding equity awards (≈2.6 m shares), legacy warrants (≈10 m at $3.76) and future ATM sales ($57.9 m capacity). Inovio remains a clinical-stage biotech with no product revenue, significant accumulated deficits, and multiple R&D, regulatory, manufacturing and financing risks.
• Corporate status: Inovio is a “smaller reporting company,” enabling reduced SEC disclosure. Piper Sandler is sole book-running manager.

Because amounts are placeholders, the filing primarily signals intent to strengthen the balance sheet ahead of key regulatory catalysts rather than conveying finalized financial impact.

Inovio Pharmaceuticals, Inc. (Nasdaq: INO) has filed a preliminary prospectus supplement under its effective shelf to raise capital through a combined offering of: (i) shares of common stock or pre-funded warrants (exercise price $0.001) in lieu of common stock, (ii) Series A warrants, and (iii) Series B warrants. Every share (or pre-funded warrant) will be sold together with one Series A warrant and one Series B warrant, although the securities are immediately separable upon issuance.

• Pricing & size: Key economics—number of securities, combined public price, underwriting discount, and gross/net proceeds—remain blank pending final marketing, but the filing authorizes a 30-day overallotment option for additional shares and warrants.
• Warrant profile: • Series A warrants are exercisable immediately, expire on the earlier of (a) 30 days after FDA accepts a Biologics License Application (BLA) for INO-3107 or (b) 12 months after issuance; • Series B warrants are exercisable immediately and expire five years after issuance. Neither series will be listed, limiting liquidity.
• Use of proceeds: Management plans to direct funds to (1) advancement of its DNA-medicine clinical pipeline—including a rolling BLA submission for lead asset INO-3107 in recurrent respiratory papillomatosis expected to begin mid-2025, (2) potential commercial launch preparation for INO-3107 if approved, and (3) general corporate purposes.
• Dilution & risk: The company warns that investors will incur immediate dilution; further dilution could arise from outstanding equity awards (≈2.6 m shares), legacy warrants (≈10 m at $3.76) and future ATM sales ($57.9 m capacity). Inovio remains a clinical-stage biotech with no product revenue, significant accumulated deficits, and multiple R&D, regulatory, manufacturing and financing risks.
• Corporate status: Inovio is a “smaller reporting company,” enabling reduced SEC disclosure. Piper Sandler is sole book-running manager.

Because amounts are placeholders, the filing primarily signals intent to strengthen the balance sheet ahead of key regulatory catalysts rather than conveying finalized financial impact.

Leidos Holdings, Inc. (LDOS) – Form 4 insider transaction

Chief Financial Officer Christopher R. Cage reported one transaction dated 06/30/2025.

• Acquisition: 64.1944 shares of common stock credited at $0.00 per share. The shares represent dividend-equivalent rights that were automatically reinvested in the company’s Key Executive Stock Deferral Plan.
• Post-transaction ownership: 29,288.682 indirect shares held via the deferral plan and 46,953 direct shares.

No derivative securities were involved and no sales were disclosed. The filing does not indicate any open-market purchases or dispositions; the recorded activity is routine and non-cash. Given the immaterial share amount relative to the executive’s existing holdings, the filing is unlikely to have a meaningful impact on LDOS’s share count or market perception.

Leidos Holdings, Inc. (LDOS) – Form 4 insider transaction

Chief Financial Officer Christopher R. Cage reported one transaction dated 06/30/2025.

• Acquisition: 64.1944 shares of common stock credited at $0.00 per share. The shares represent dividend-equivalent rights that were automatically reinvested in the company’s Key Executive Stock Deferral Plan.
• Post-transaction ownership: 29,288.682 indirect shares held via the deferral plan and 46,953 direct shares.

No derivative securities were involved and no sales were disclosed. The filing does not indicate any open-market purchases or dispositions; the recorded activity is routine and non-cash. Given the immaterial share amount relative to the executive’s existing holdings, the filing is unlikely to have a meaningful impact on LDOS’s share count or market perception.

Clarivate Plc (CLVT) – Form 4 insider transaction filed 07/02/2025.

Director Andrew M. Snyder reported routine quarterly equity compensation in lieu of a cash retainer. On 06/30/2025 he acquired 11,918 ordinary shares at the 06/30/2025 closing price of $4.30, equivalent to the $51,250 board fee. To cover withholding taxes, 527 shares were surrendered at the same price. After these transactions Mr. Snyder holds 164,489 shares directly.

In addition, Snyder has large indirect holdings totalling 24,374,148 shares through Cambridge Information Group entities and a family trust, though he disclaims beneficial ownership beyond his pecuniary interest.

No options or other derivative securities were reported. The filing reflects normal director compensation rather than a discretionary open-market purchase, so market impact is expected to be minimal.